chlorthalidone has been researched along with Disease Exacerbation in 4 studies
Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 33,357 patients (aged ≥ 55 years) with hypertension and at least 1 other coronary heart disease (CHD) risk factor were randomized to chlorthalidone, amlodipine, or lisinopril." | 5.24 | Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study. ( Bang, CN; Davis, BR; Devereux, RB; Okin, PM; Simpson, LM; Soliman, EZ, 2017) |
| "The composite outcome included incident ESRD after assessment of SD of systolic BP or ≥50% decline in eGFR between 24 months and 48 or 72 months after randomization." | 1.43 | Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT. ( Davis, BR; Lynch, AI; Muntner, P; Oparil, S; Rahman, M; Simpson, LM; Tanner, RM; Whelton, PK; Whittle, J, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bang, CN | 1 |
| Soliman, EZ | 1 |
| Simpson, LM | 2 |
| Davis, BR | 2 |
| Devereux, RB | 1 |
| Okin, PM | 1 |
| Fuchs, FD | 1 |
| Fuchs, SC | 1 |
| Poli-de-Figueiredo, CE | 1 |
| Figueiredo Neto, JA | 1 |
| Scala, LCN | 1 |
| Vilela-Martin, JF | 1 |
| Moreira, LB | 1 |
| Chaves, H | 1 |
| Mota Gomes, M | 1 |
| de Sousa, MR | 1 |
| Silva, RPE | 1 |
| Castro, I | 1 |
| Cesarino, EJ | 1 |
| Sousa, ALL | 1 |
| Alves, JG | 1 |
| Steffens, AA | 1 |
| Brandão, AA | 1 |
| Bortolotto, LA | 1 |
| Afiune Neto, A | 1 |
| Nóbrega, AC | 1 |
| Franco, RS | 1 |
| Sobral Filho, DC | 1 |
| Nobre, F | 1 |
| Schlatter, R | 1 |
| Gus, M | 1 |
| De David, CN | 1 |
| Rafaelli, L | 1 |
| Sesin, GP | 1 |
| Berwanger, O | 1 |
| Whelton, PK | 2 |
| Whittle, J | 1 |
| Lynch, AI | 1 |
| Tanner, RM | 1 |
| Rahman, M | 1 |
| Oparil, S | 1 |
| Muntner, P | 1 |
| Nakagawa, T | 1 |
| Johnson, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| Prevention of Hypertension in Patients With Pre-hypertension: PREVER-prevention Study[NCT00970931] | Phase 3 | 730 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Uric Acid and Hypertension in African Americans[NCT00241839] | Phase 3 | 150 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Diastolic BP was taken at Baseline and after 8-10 weeks of treatment or placebo while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol / placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 3.44 |
| B (Placebo) | -0.83 |
Subjects had 24 hr blood pressure monitoring (ABPM) at baseline and treatment end. The readings were averaged and the changes from baseline to treatment end were compared. (NCT00241839)
Timeframe: Baseline and end of treatment (8-10 weeks on allopurinol / placebo)
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | -5.9 |
| B (Placebo) | 0.90 |
"The systolic BP was taken at Baseline and after 8-10 weeks of treatment on placebo, while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol or placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 0.21 |
| B (Placebo) | -0.95 |
Subjects on allopurinol are expected to lower their uric acid levels relative to placebo. (NCT00241839)
Timeframe: Baseline UA levels compared to end of treatment levels (8-10 weeks on allopurinol / placebo)
| Intervention | mg/dl (Mean) |
|---|---|
| A (Allopurinol) | 2.29 |
| B (Placebo) | 0.14 |
2 trials available for chlorthalidone and Disease Exacerbation
| Article | Year |
|---|---|
Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cause of Death; Chlorthalidone; Disease P | 2017 |
Effectiveness of low-dose diuretics for blood pressure reduction to optimal values in prehypertension: a randomized clinical trial.
Topics: Adult; Amiloride; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diastole; Disease Progres | 2018 |
2 other studies available for chlorthalidone and Disease Exacerbation
| Article | Year |
|---|---|
Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT.
Topics: Aged; Amlodipine; Antihyperkalemic Agents; Blood Pressure; Blood Pressure Determination; Chlorthalid | 2016 |
Hypertension: Is there a dark side to thiazide therapy for hypertension?
Topics: Chlorthalidone; Chronic Disease; Disease Progression; Diuretics; Humans; Hypertension; Kidney Diseas | 2010 |